Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002046 · ClinicalTrials.gov registry record · NA

A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC

A NA study of HIV Infections, sponsored by Glaxo Wellcome.

Completed
Registry status
NA
Development phase
11
Study locations

NCT00002046 is a NA study of HIV Infections that has completed, run by Glaxo Wellcome. The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002046, a NA study of HIV Infections, has completed, sponsored by Glaxo Wellcome.

COMPLETED
Registry status
NA
Development phase
11
Study locations

Study Summary

To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in the treatment of patients with severe clinical and laboratory manifestations of HIV infection. To compare the safety and tolerance of AZT administered 2, 3, and 6 x daily to these patients.

Conditions Studied

Interventions

  • DRUG Zidovudine

Study Locations (11)

Illinois

  • Northwestern Univ Med School - Chicago
  • Cook County Hosp - Chicago
  • Rush Presbyterian - Saint Luke's Med Ctr - Chicago

Texas

  • Univ TX Galveston Med Branch - Galveston
  • Baylor College of Medicine - Houston

Arizona

  • Univ of Arizona / Health Science Ctr - Tucson

Maryland

  • Johns Hopkins Hosp - Baltimore

Missouri

  • Univ of Missouri at Kansas City School of Medicine - Kansas City

New Mexico

  • Univ of New Mexico Hlth Sciences Ctr / Dept of Med - Albuquerque

New York

  • Northshore Hosp / Cornell Univ - Manhasset

Pennsylvania

  • Univ of Pennsylvania / HIV Clinic - Philadelphia

Trial Details

FieldValue
Phase NA

Sponsor

Glaxo Wellcome

65 total trials

What the Registry Record Tells You About NCT00002046

The ClinicalTrials.gov registry entry for NCT00002046 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Zidovudine is the first listed.

NCT00002046 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Illinois, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT00002046 about?

NCT00002046 is a clinical study titled "A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC". To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in the treatment of patients with severe clinical and laboratory manifestations of HIV infection. To compare the safety and tolerance of AZT administered 2, 3, and 6 x daily to these patients.

What is the current status of trial NCT00002046?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002046 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002046?

The interventions under investigation include: Zidovudine (DRUG).

Who is sponsoring clinical trial NCT00002046?

This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002046 being conducted?

This trial has 11 study locations across Arizona, Illinois, Maryland, Missouri, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.